<< World’s first Cesium-131 lung implants performed | CryoLife reports a net income of $1.9 million for the third quarter of 2009 >>
Read in | English | Español | 日本語 | Bahasa

Inhibitex completes $23 million private placement of common stock and warrants

Published on October 29, 2009 at 9:16 AM · No Comments

Inhibitex, Inc. (Nasdaq: INHX) today reported the completion of its previously announced $23 million private placement of common stock and warrants. Investors in the private placement purchased units, each consisting of one share of common stock and a warrant to purchase .45 of a share of common stock, at a purchase price of $1.28 per unit, which is equal to the consolidated closing bid price of the common stock as reported on the NASDAQ Capital Market for October 22, 2009, plus $0.06. The warrants have an exercise price equal to $1.46 per share, and expire on October 28, 2013.

The shares and warrants sold in the private placement and the shares issuable upon the exercise of the related warrants have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or state securities laws, and may not be offered or sold in the United States without being registered with the Securities and Exchange Commission ("SEC") or through an applicable exemption from SEC registration requirements. The shares and warrants were offered and sold only to accredited investors. Inhibitex has agreed to file a registration statement with the SEC covering the resale of the shares issued in the private placement and the shares issuable upon the exercise of the warrants.

SOURCE Inhibitex

Posted in:

Tags: , , ,

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading